In the end, all the above proposals aim to complement the “classical” MIPI data with different surrogate markers of aggressiveness and are mostly limited by inter-individual tumor heterogeneity, sampling and analysis standardization and, although of great interest, only Ki-67 and TP53 mutations have been validated so far [41]. This evidence concerns the gene TP53 and neoplasm.